Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 2/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | MMP12 | P39900 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8000296 | 0.79 | CA2 (0.48) | ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7997568 | 0.79 | HTR6 (0.38) | ALDH1A1MAPTLMNAKDM4E | |
| SCHEMBL1178907 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPTLMNAKDM4EHTT | |
| SCHEMBL3618541 | 0.72 | MAPT (1.00) | ALDH1A1MAPTLMNAKDM4EHTT | |
| SCHEMBL8001021 | 0.72 | HTR6 (0.44) | — | |
| SCHEMBL26028733 | 0.72 | MAOB (0.47) | MAPTHTTSMN1; SMN2SLC6A2 | |
| SCHEMBL12567063 | 0.71 | CYP3A4 (0.41) | HTTKMT2AMMP13SLC6A2MMP12 | |
| SCHEMBL12886466 | 0.70 | HTT (0.67) | ALDH1A1MAPTLMNAKDM4EHTT | |
| SCHEMBL16130747 | 0.68 | NPC1 (0.33) | MAPTMMP13SLC6A2MMP12 | |
| SCHEMBL10249975 | 0.67 | CYP4F2 (0.52) | MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265589-B1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LTD (BS) | 2016-01-27 | — | — | EP | disclosed |
| US-9126942-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2015-09-08 | — | — | US | disclosed |
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBVIE BAHAMAS LIMITED (BS) | 2015-02-19 | — | — | US | disclosed |
| US-8901108-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBVIE BAHAMAS LIMITED (BS) | 2014-12-02 | — | — | US | disclosed |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HEALTHCARE PRODUCTS B.V. (NL) | 2014-01-09 | — | — | US | disclosed |
| US-8563723-B2 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | ABBOTT HEALTHCARE PRODUCTS, B.V. (NL) | 2013-10-22 | — | — | US | disclosed |
| EP-2610247-A1 | Arylsulfonyl pyrazoline carboxamidine derivatives as 5-HT6 antagonists | Abbott Healthcare Products B.V. (NL) | 2013-07-03 | — | — | EP | disclosed |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | ABBOTT HOSPITALS LIMITED (BS) | 2011-02-24 | — | — | US | disclosed |
| WO-2009115515-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051239-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | ALDH1A1 2125/4885MAPT 581/4885LMNA 4603/4885 |
| US-20110046171-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | ALDH1A1 2125/4885MAPT 581/4885LMNA 4603/4885 |
| US-20140011775-A1 | ARYLSULFONYL PYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS | HTR6, HTR2C, HTR4 | ALDH1A1 2125/4885MAPT 581/4885LMNA 4603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.